RTTNews | Sep 17, 2021 09:32AM EDT

09:32 Friday, September 17, 2021 (RTTNews.com) - Corcept Therapeutics Inc. (CORT) said that results from its 178-patient, randomized, controlled, Phase 2 trial of relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer were featured in a proffered paper oral presentation at the European Society for Medical Oncology Congress 2021.

The results showed statistically significant and clinically relevant benefit experienced by women with recurrent platinum-resistant ovarian cancer who were treated with nab-paclitaxel plus Corcept's proprietary selective cortisol modulator, relacorilant.

Corcept Therapeutics noted thar the results presented at ESMO today demonstrated the benefit experienced by the women who received relacorilant - delayed disease progression without increased side effect burden. The company and its investigators are excited to begin a pivotal Phase 3 trial in the first quarter of next year to confirm these results.

Women who received the higher dose of relacorilant intermittently exhibited a statistically significant improvement in median progression free survival (PFS) compared to those who received nab-paclitaxel alone.

The women in the Intermittent arm also experienced a statistically significant improvement in the duration of response (DoR) relative to those in the Comparator arm.

While the overall survival (OS) data was only 63% mature at the time of the database cut-off, the women in the Intermittent arm exhibited a median OS of 12.9 months versus 10.4 months in the Comparator arm.

Read the original article on RTTNews ( https://www.rttnews.com/3226581/corcept-therapeutics-presents-positive-results-from-phase-2-trial-of-relacorilant-on-ovarian-cancer.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved